SEC Filing Summary: SIGA Technologies, Inc. (Form 8-K)
Business Context and Reporting Period
Company: SIGA Technologies, Inc.
Filing Date: September 10, 2018
Reporting Period: Event date of September 10, 2018
Context: The Company announced the execution of a multi-year contract with the Biomedical Advanced Research and Development Authority (BARDA) for the delivery and development of TPOXX, an antiviral treatment for smallpox.
Key Financial Metrics and Contract Value
This filing reports on a material definitive agreement rather than periodic financial results. Key contract values include:
- Total Contract Value: Up to $629 million (if all options are exercised).
- Base Period Value: Approximately $52 million.
- Option Value: Approximately $577 million (exercisable at BARDA's sole discretion).
- Contract Duration: Five-year base period with options extending up to ten years.
Note: The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the Company's financial statements.
Material Changes and Contract Details
The New BARDA Contract represents the third active agreement between SIGA and BARDA. Key components include:
- Base Period Activities ($52 million):
- Development of the intravenous (IV) formulation of TPOXX.
- Delivery of approximately 35,700 courses of oral TPOXX (valued at ~$11 million).
- Manufacture and delivery of 20,000 courses of IV TPOXX (valued at ~$8 million).
- Option Activities ($577 million):
- Procurement of up to 1,452,300 additional courses of oral TPOXX (up to ~$450 million).
- Procurement of up to 192,000 courses of IV TPOXX or equivalent bulk drug substance (up to ~$77 million or ~$31 million).
- Vendor-managed storage options (up to ~$6 million).
- Post-marketing activities funding (up to ~$44 million).
The contract aims to maintain a Strategic National Stockpile of 1.7 million courses of antiviral treatment.
Outlook, Risks, and Management Commentary
Management Commentary: The contract supports the transition of patients from IV therapy to oral therapy once they are able to swallow capsules. The IV formulation is intended for patients too sick to take oral capsules.
Risks and Contingencies:
- Discretionary Options: The majority of the contract value ($577 million) is contingent upon BARDA exercising options at its sole discretion.
- Regulatory Context: The contract follows the FDA approval of oral TPOXX on July 13, 2018.
Investor Verification Checklist
- Verify the specific terms and exercise conditions of the $577 million in options, as they are not guaranteed revenue.
- Review the full text of the contract (Exhibit 10.1) for omitted portions filed under confidential treatment.
- Confirm the timeline for the delivery of the 35,700 oral TPOXX courses and 20,000 IV TPOXX courses included in the base period.
- Assess the Company's manufacturing capacity to fulfill the potential 1.7 million course stockpile requirement.